KevinMD December 30, 2025
As a physician-psychiatrist, I have watched the rise of GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) with genuine admiration. They are transforming metabolic health, reducing cardiovascular risk, and offering hope to patients who have struggled for decades. For many, these medications are lifesaving.
But alongside the excitement, I’m witnessing something rarely discussed: a change in personality and affect, especially at higher doses.
This pattern reminds me of the early days of SSRIs. When fluoxetine was introduced, it was hailed as a medication that could reduce neuroticism and even “improve personality.” Only later did we fully recognize the trade-offs: emotional blunting, loss of motivation, reduced libido, and a subtle flattening of the inner emotional landscape.
Today, with GLP-1s, I’m observing a similar...
Today's Sponsors
Today's Sponsor